



FEBRUARY 27 & 28



MDAnderson
~~Cancer~~ Center
Madrid • España



MDAnderson
~~Cancer~~ Center
Fundación • España

SOHO **SPAIN** 2025

Rafael del Pino auditorium C. de Rafael Calvo 39A 28010
Madrid, Spain




SOHO **SPAIN** 2025

A Society of Hematologic Oncology Regional/Satellite Meeting

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO's mission is to expedite worldwide research and education through the exchange of scientific information.

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies, and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 9,500 members from 110 countries have joined the society from around the globe. To become a SOHO member, go to www.soho.click/join and access the resources available exclusively to members. SOHO membership is free-of-charge. If you have any questions, you can contact SOHO membership at admin@soho.org.



February 27&28

Honorary President

Dr. Hagop Kantarjian

Dra. María Victoria Mateos

Spanish Scientific committee

- **Dra. Ana Sureda**
- **Dra. María Díez Campelo**
- **Dr. Carlos Fernández de Larrea**
- **Dr. Pau Montesinos**
- **Dr. Carlos Panizo**
- **Dr. Ramón García-Sanz**
- **Dr. Fernando Martín Moro**
- **Dr. Valentín García Gutiérrez**
- **Dr. Francesc Bosch**

Directors


Dr. Guillermo García-Manero

University of Texas MD Anderson Cancer Center, Houston, USA

Dr. Adolfo de la Fuente Burguera

MD Anderson Cancer Center Madrid - Hospiten, Spain

International Scientific committee

- **Dr. Alessandro Isidori**
 - **Dr. Claudio Cerchione**
 - **Dr. Elías Jabbour**
 - **Dr. Naval Daver**
- 

• 9:30h - 9:40h Welcome

Phil Scheinberg

Hospital A Beneficência Portuguesa *São Paulo, Brazil*

Guillermo García-Manero

University of Texas MD Anderson Cancer Center, *Houston, USA*

Adolfo de la Fuente

MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

1. Multiple Myeloma (MM): Controversies in treatment

Moderator: **Carlos Fernández de Larrea**

Hospital Clinic of Barcelona. *Barcelona, Spain*

Moderator: **Verónica González de la Calle**

University Hospital of Salamanca. *Salamanca, Spain*

• 9:40h - 10:10h **First-line treatment: Bortezomib, lenalidomide, and anti-CD38 for all?**

Aurore Perrot

Toulouse University Hospital. *Toulouse, France*

• 10:10h - 10:30h **How to treat at relapse? Antibody-based approaches**

Niels van de Donk

Amsterdam University Medical Center. *Amsterdam, Netherlands*

• 10:30h - 10:50h **How to treat at relapse? CAR-T cell-based strategies**

Luis Gerardo Rodríguez

Clinical Hospital of Barcelona. *Barcelona, Spain*

• 10:50h - 11:20h **Discussion:** All speakers and moderators

• **11:20h - 11:40h** **Breaking News**

Claudio Cerchione

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino
Amadori" - IRST. *Meldola, Italy*

• **11:40h - 11:55h** **COFFEE BREAK**

2.Chronic Myeloid Leukemia (CML)

Moderator: Valentín García Gutiérrez

Ramón y Cajal University Hospital. *Madrid, Spain*

Moderator: Alicia Senin

Hospital Del Mar. *Barcelona, Spain*

• **11:55h - 12:15h** **Prognostic implications of cancer-associated mutations in CML**

Gonzalo Carreño

12 de Octubre University Hospital. *Madrid, Spain*

• **12:15h - 12:35h** **First-line therapy updates in CML patients**

Valentín García Gutiérrez

Ramón y Cajal University Hospital. *Madrid, Spain*

• **12:35h - 12:55h** **Treatment discontinuation in CML: Who, how, and when?**

Santiago Osorio

Gregorio Marañón, University Hospital. *Madrid, Spain*

• **12:55h - 13:10h** **Discussion**

3. Myelodysplastic Syndromes (MDS)

Moderator: **María Díez Campelo**

University of Salamanca. *Salamanca, Spain*

Moderator: **Adolfo de la Fuente**

MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

• **13:10h - 13:30h Rethinking classification and prognosis in MDS**

Rami Komrokji

Moffit Cancer Center. *Houston, USA*

• **13:30h - 13:50h How to avoid transfusion dependence in low-risk MDS**

Valeria Santini

University of Florence Medical School. *Florence, Italy*

• **13:50h - 14:10h Targeted therapy and new targets in high-risk MDS**

Guillermo García-Manero

University of Texas MD Anderson Cancer Center. *Houston, USA*

• **14:10h - 14:25h Discussion**

IDEOGEN Symposium Program

• **14:25h - 15:10h Advances in the management of T lymphomas: from the disease to clinical solutions**

Ana García Noblejas

Princess Hospital. *Madrid, Spain*

Alejandra Blum

Campo Grande Hospital, Recoletas Group. *Valladolid, Spain*

Beatriz Urrego

General Hospital of Catalunya. *Barcelona, Spain*

- **15:10h - 15:55h LUNCH** Sponsored by GSK

4. Acute Myeloid Leukemia (AML) NOVEL TARGETED THERAPIES FOR AML

Moderator: **Adolfo de la Fuente**

MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

Moderator: **Pau Montesinos**

La Fe Polytechnic University Hospital. *Valencia, Spain*

- **15:55h - 16:15h Menin inhibitors for AML. What does the future look like?**

Cristina Papayannidis

IRCCS Azienda Ospedaliero-Universitaria di Bologna. *Bologna, Italy*

- **16:15h - 16:35h Emerging triplets and doublets with FLT3 inhibitors**

Juan Bergua

San Pedro de Alcántara Hospital. *Cáceres, Spain*

- **16:35h - 16:55h Current developments of IDH inhibitors: beyond ivosidenib for unfit AML patients**

Rebeca Rodríguez

La Fe Health Research Institute IIS La Fe. *Valencia, Spain*

- **16:55h - 17:10h Discussion**

- **17:10h - 17:25h COFFEE BREAK**

5.Lymphoma 1

Moderator: **Juan Fernando García García**

MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

Moderator: **Ramón García Sanz**

Gregorio Marañón General University Hospital. *Madrid, Spain*

Moderator: **Fernando Martín Moro**

Ramón y Cajal University Hospital. *Madrid, Spain*

- **17:25h - 17:45h Lymphoma Classification How to develop a Future Unified Taxonomy**

Miguel Ángel Piris

Jiménez Díaz Foundation. *Madrid, Spain*

- **17:45h - 18:05h Towards targeted treatments on the front line**

Alejandro Martín García Sancho

University Hospital of Salamanca. *Salamanca, Spain*

- **18:05h - 18:25h Diffuse Large B-cell lymphoma sequencing of therapies in the relapse setting**

Miguel Canales

University Clinic of Navarra. *Pamplona, Spain*

- **18:25h - 18:45h Multidisciplinary approach in cutaneous T cell lymphoma**

Miriam López Parra

University Hospital of Salamanca. *Salamanca, Spain*

- **18:45h - 19:00h Discussion**

February 27

Pre-dinner sympo

Advancing individualization of treatment in Chronic Lymphocytic Leukemia (CLL)

Moderator: **Javier de la Serna**

12 de Octubre University Hospital. *Madrid, Spain*

• 19:00h - 20:00h Highlights CLL

Lucrecia Yañez Marqués de Valdecilla

Marqués de Valdecilla University Hospital – IDIVAL University of Cantabria. *Cantabria, Spain.*

Panel discussion:

Individualization of treatment beyond cytogenetics

José Antonio García Vela

Puerta De Hierro University Hospital. *Madrid, Spain*

Almudena Navarro

University Hospital of Salamanca. *Salamanca, Spain*

• 21:00h

DINNER Sponsored by SANOFI

Restaurant: Fortuny Home Club

Address: C. de Fortuny, 34

SERB Symposium Program

Moderator: **Adolfo de la Fuente**

MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

Moderator: **Jaime Verdú Amorós**

Hospital University Valencia. *Valencia, Spain*

• 8:00h - 8:05h **Welcome**

Challenges in the management of patients treated with HDMTX

Adolfo de la Fuente

MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

• 8:05h - 8:25h **Review of guidelines and protocols for the management of adult patients treated with HDMTX**

Anna Torrent Catarineu

Catalan Institute of Oncology | Clinical Hematology | Germans Trias i Pujol Hospital. *Barcelona, Spain*

• 8:25h - 8:50h **Glucarpidase (Voraxaze®) in acute MTX toxicity. Early diagnosis of delayed methotrexate elimination. “A European consensus recommendation on the treatment of late elimination of methotrexate: supportive measures, leucovorin rescue and glucarpidase treatment.”**

Thais Murciano Carrillo

Vall d’Hebron University Hospital. *Barcelona, Spain*

• 8:50h - 9:00h **Questions and discussion**

• 9:00h - 9:10h

1. Introduction to the Chronic Lymphocytic Leukemia (CLL)

Moderator: **Francesc Bosch**

Vall d'Hebron Hospital. *Barcelona, Spain*

Moderator: **Juan Marquet Palomanes**

Ramón y Cajal University Hospital. *Madrid, Spain*

Moderator: **José Francisco Tomás**

La Moraleja University Hospital / Virgen del Mar University Hospital. *Madrid, Spain*

• 9:10h - 9:20h

Continuous vs. time-limited treatment

• 9:20h - 9:30h

Continuous vs. time-limited treatment - In favor of continuous strategies

Javier Loscertales

La Princesa University Hospital. *Madrid, Spain*

• 9:30h - 9:40h

Continuous vs. time-limited treatment - In favor of time-limited strategies (**Straming session**)

Othman Al-Sawaf

University Hospital Cologne. *Cologne, Germany*

• 9:40h - 9:50h

Continuous vs. time-limited treatment - Discussion

• 9:50h - 10:00h

Continuous vs. time-limited treatment

• 10:00h - 10:15h

Sequencing treatment after front-line BTKi

Almudena Navarro

University Hospital of Salamanca. *Salamanca, Spain*

• **10:15h - 10:30h Sequencing treatment after time-limited therapy**

Lucrecia Yáñez

Marqués de Valdecilla University Hospital - IDIVAL

University of Cantabria. *Cantabria, Spain*

• **10:30h - 10:45h Richter transformation**

Pau Abrisqueta

Vall d'Hebron Hospital. *Barcelona, Spain*

• **10:45h - 11:00h COFFEE BREAK**

2.Negative Philadelphia Myeloproliferative Neoplasms

Moderator: Valentín García Gutiérrez

Ramón y Cajal University Hospital *Madrid, Spain*

Moderator: Lucía Pérez Lamas

Puerta de Hierro University Hospital. *Madrid, Spain*

• **11:00h - 11:20h New developments in diagnosis and molecular monitoring of Philadelphia-negative myeloproliferative neoplasms**

Beatriz Bellosillo

Hospital del Mar. *Barcelona, Spain*

• **11:20h - 11:40h Interferon in Polycythemia Vera, how, when and to whom?**

Miguel Piris

Ramón y Cajal University Hospital. *Madrid, Spain*

• **11:40h - 12:00h Optimizing Treatment for Myelofibrosis:
A Personalized Approach**

Francesca Palandri

IRCCS Azienda Ospedaliero-Universitaria di Bologna. *Bologna, Italy*

• **12:00h - 12:15h Discussion**

3.Lymphoma 2

Moderator: Carlos Montalbán

MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

Moderator: Ramón García Sanz

Gregorio Marañón General University Hospital, *Madrid, Spain*

Moderator: Sara Alonso Álvarez

Hospital Universitario Central de Asturias. ISPA. IUOPA. *Oviedo, Spain*

• **12:15 - 12:35h Breaking News**

Luis Fayad

MD Anderson Cancer Center. *Houston, USA*

• **12:35h - 12:55h Advanced Hodgkin lymphoma: can we improve
first-line treatment? (Straming session)**

Peter Borchmann

University Hospital of Cologne. *Cologne, Germany*

• **12:55h - 13:15h Choosing Between a BTK Inhibitor & Car T-Cell
Therapy in RR MCL**

Ana Marín Niebla

Vall d'Hebron University Hospital. *Barcelona, Spain.*

• **13:15h - 13:35h Discussion**

DAIICHI SANKYO Symposium Program

How molecular information guide treatment decisions

Moderator: **Adolfo de la Fuente**

MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

Moderator: **Claudia Núñez-Torrón Stock**

Infanta Sofía University Hospital. *Madrid, Spain*

• 13:35h - 14:20h Genetic study in myeloblastic leukemia at diagnosis

Margarida Coucelo

Pediatric Hospital of Coimbra. *Coimbra, Portugal*

The evolving role of FLT3 inhibitors for AML

Adolfo de la Fuente

MD Anderson Cancer Center Madrid – Hospiten *Madrid, Spain*

• 14:20h - 15:30h **LUNCH**

4. Transplant and Cell Therapy

Moderator: **Ana Alarcón Tomás**

Puerta de Hierro University Hospital. *Madrid, Spain*

Moderator: **Carlos Panizo**

Donostia University Hospital. *San Sebastián, Spain*

Moderator: **Ana Sureda**

Catalan Institute of Oncology (ICO). *Barcelona, Spain*

• 15:30h - 15:50h CART cells in acute myeloblastic leukemia

Nela Klein

Hospital Clinic Barcelona. *Barcelona, Spain*

- **15:50h - 16:10h** **Post-CART relapses in patients with B lymphoma: Mechanisms of resistance and potential therapeutic strategies. (Streaming session)**

Roni Shouval

Memorial Sloan Kettering Cancer Center, New York, USA

- **16:10h - 16:30h** **Role of hematopoietic stem cell transplantation in lymphomas in 2025**

Leyre Bento

Son Espases Hospital. Palma de Mallorca, Spain

- **16:30h - 16:45h** **Discussion**

- **16:45h - 17:00h** **COFFEE BREAK**

5.Lymphoma 3

Moderator: Carlos Montalbán

MD Anderson Cancer Center Madrid - Hospiten. Madrid, Spain

Moderator: Alejandro Bobes

MD Anderson Cancer Center Madrid - Hospiten. Madrid, Spain

Moderator: Carlos Panizo

Donostia University Hospital. San Sebastián, Spain

- **17:00h - 17:20h** **Follicular Lymphoma management algorithm in 2025**

Armando López Guillermo

Hospital Clinic of Barcelona. Barcelona, Spain

- **17:20h - 17:40h** **POD24 it's not all the same**

Ana Muntañola

Hospital de la Santa Creu i Sant Pau. Barcelona, Spain

- **17:40h - 17:50h** **Discussion**

• 17:50h - 18:10h **Breaking News in Acute Leukemia**

Moderator: **Luis Pedro Monteiro**

ULS São José. *Lisbon, Portugal*

Moderator: **Carlos Jiménez Chillón**

Gregorio Marañón University Hospital. *Madrid, Spain*

Myeloblastic Leukemia

Naval Daver

MD Anderson Cancer Center. *Houston, US*

Lymphoblastic Leukemia

Elías Jabbour

MD Anderson Cancer Center. *Houston, US*

6.Acute Myeloid Leukemia (AML) From clinical trials to real-life data in AML

Moderator: **Adolfo de la Fuente**

MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

Moderator: **Pau Montesinos**

La Fe Polytechnic University Hospital. *Valencia, Spain*

• 18:10h - 18:30h **Real world practice with Venetoclax-based regimens for unfit AML**

Stephane de Botton

Institut Gustave Roussy. *Paris, France*

• 18:30h - 18:50h **International experience with CPX-351 for high-risk fit AML**

Teresa Bernal

Central University Hospital of Asturias. *Oviedo, Spain*

• 18:50h - 19:05h **Discussion**

February 28

• 19:05h - 19:10h **Farewell**

Phil Scheinberg

Hospital A Beneficência Portuguesa São Paulo, Brazil

Guillermo García-Manero

University of Texas MD Anderson Cancer Center. Houston, USA

Adolfo de la Fuente

MD Anderson Cancer Center Madrid - Hospiten, Spain.

Madrid, Spain

Organized by



MDAnderson
Cancer Center
Madrid • España

 **Hospiten**

MDAnderson
Cancer Center
Fundación • España



SPONSORS

PLATINUM

AstraZeneca 

SERVIER 
moved by you

GOLD

 **SERB**
Pharmaceuticals

SPONSORS

SILVER

abbvie



Johnson
& Johnson



Lilly

BRONZE





SPONSORS

COLLABORATOR



sanofi

The oncopeptides logo features a white circular icon with concentric lines, followed by the word "oncopeptides" in a white, sans-serif font, all set against an orange rectangular background.

oncopeptides

AMGEN®



Organized by



MDAnderson
Cancer Center
Madrid · España



MDAnderson
Cancer Center
Fundación · España

Accreditation

Credits requested from the Continuing Education Commission
of Health Professions of the Community of Madrid

Venue

Rafael del Pino auditorium C. de Rafael Calvo 39A 28010
Madrid, Spain

Technical Secretary



BioPress Ediciones Médicas SL
C/Velázquez, 59, 5º Cl. 28001, MADRID
ESPAÑA